Clinical Trial

A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 20, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to evaluates the efficacy of weekly nab-paclitaxel monotherapy compared to the standard regimen of docetaxel plus carboplatin, both supplemented with trastuzumab and pertuzumab, as neoadjuvant therapies for HER2-positive breast cancer.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2020-09-08; most recent amendment 2024-09-18.
Trial Details
NCT Number NCT04547907
Lead Sponsor Henan Cancer Hospital
Conditions Breast Cancer,HER2-positive
Enrollment 688 participants
Start Date 2020-09-18
Primary Completion 2024-12-31 (estimated)
Study Completion 2024-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-09-20